AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Upregulation of urokinase plasminogen activator by the HER-2/neu oncogene appears to occur in the early stage of cervical cancer in patients, according to recent research.
"It has been suggested that urokinase plasminogen activator (uPA) in cancer cells is upregulated by the p185 kD form of the HER-2/neu oncogene," said obstetrician/gynecologists at Long Island Jewish Medical Center, New York.
D.N. Contreras and colleagues investigated whether "the extracellular domain of HER-2/neu, the p105 fraction, which is found in the circulation, has any regulatory influence on uPA in patients with cervical cancer."
According to their report, "Levels of uPA and p105 HER-2/neu were determined in blood from age-matched controls and patients with early and advanced cervical cancer. In the patients with cervical cancer, samples were obtained before treatment only."
"No significant increase in either uPA or HER-2/neu was seen in the patients before their treatment for cervical cancer. Additionally, correlation analysis of circulating uPA and HER-2/neu against each other in both the controls and cervical cancer indicated no relationship except in early stage disease," wrote ...